Why Prescription Drugs Cost So Much — The Complete Picture
The United States pays more for prescription drugs than any other country in the world — often two to ten times more for the same medication. The reasons are structural, layered, and deeply contested. This guide explains the full chain from drug manufacturer to pharmacy counter, who profits at each step, and what recent policy changes have and have not done about it.
Why US Drug Prices Are Higher Than Everywhere Else
INDUSTRY ARGUES
Drug development is extraordinarily expensive and risky — the average cost to bring a new drug to market exceeds $2 billion when accounting for failed trials. US prices reflect the true cost of innovation. Other countries free-ride on American investment by imposing price controls, leaving US patients to subsidise global drug development. Without strong pricing in the US market, investment in new treatments would decline.
CRITICS ARGUE
Many high-priced drugs were developed with significant public funding through NIH grants and government research partnerships. Pharmaceutical companies spend more on marketing than R&D. The $2 billion figure includes failed drugs and uses accounting methods critics dispute. Countries with price controls continue to receive new drugs, suggesting manufacturers accept lower prices rather than abandon large markets.
The Role of Patents and Market Exclusivity
Drug patents give manufacturers exclusive rights to produce a drug for a defined period — typically 20 years from the date of filing, though by the time a drug reaches market the effective patent life is often 12-14 years. During this period the manufacturer faces no generic competition and can set prices without restraint. When patents expire generic manufacturers can enter the market, and prices typically fall dramatically — often by 80-90% within a few years of generic entry.
The pharmaceutical industry has developed strategies to extend effective exclusivity beyond the original patent period. Evergreening involves making minor modifications to a drug — a new formulation, dosing schedule, or delivery mechanism — and patenting the modification, allowing the manufacturer to move patients to the new version before generic competition arrives. Pay-for-delay agreements, in which brand manufacturers pay generic competitors to delay market entry, were curtailed by a 2013 Supreme Court ruling but continue in modified forms.
Pharmacy Benefit Managers — The Hidden Middlemen
Between drug manufacturers and patients sits a layer of intermediaries called pharmacy benefit managers — PBMs — that most Americans have never heard of despite the fact that they shape what drugs are covered by insurance and at what cost. Three PBMs — CVS Caremark, Express Scripts, and OptumRx — manage prescription drug benefits for roughly 80% of Americans with insurance coverage.
WHAT PBMs ACTUALLY DO
PBMs negotiate rebates with drug manufacturers in exchange for preferred placement on insurance formularies. A manufacturer might pay a 40% rebate to have its drug listed as a preferred tier-2 drug rather than a non-preferred tier-3 drug that patients pay more for. These rebates — estimated at over $100 billion annually — are negotiated in private. Critics argue PBMs have an incentive to prefer high-list-price drugs that generate large rebates over lower-cost alternatives that would save patients money. The FTC launched a major investigation into PBM practices in 2022, with preliminary findings released in 2024 describing practices that inflate costs for patients and employers.
PBMs ARGUE
PBMs provide essential services that reduce costs for plan sponsors and patients — negotiating discounts that individual employers and insurers could not achieve alone, managing complex formularies, processing billions of claims annually, and promoting the use of lower-cost generics and biosimilars. The rebates they negotiate are passed through to health plans and ultimately reduce premiums.
CRITICS ARGUE
The rebate system creates perverse incentives — PBMs earn more when list prices are higher, so they have little motivation to push manufacturers to lower prices. Patients pay cost-sharing based on list price rather than the net price after rebates, meaning they are paying a share of a price that nobody actually pays. Vertical integration — major PBMs are now owned by the same companies that own large pharmacy chains and insurers — creates profound conflicts of interest.
Brand Name vs Generic vs Biosimilar
Generic drugs contain the same active ingredient as the brand name drug at the same dose and must meet the same FDA standards for safety and efficacy. They typically cost 80-90% less than brand equivalents. Despite this, brand manufacturers invest heavily in keeping patients on brand drugs — through copay coupon programmes that make the brand appear cost-competitive for the patient while ensuring the insurer pays the higher brand price, and through direct-to-consumer advertising that builds brand loyalty.
Biosimilars are the generic equivalent for biologic drugs — complex medicines derived from living cells that treat conditions like rheumatoid arthritis, cancer, and diabetes. Biologics are among the most expensive drugs on the market. The US biosimilar market has been slower to develop than in Europe partly due to legal strategies by brand manufacturers to block competition and partly due to PBM practices that have favoured established brands.
The Inflation Reduction Act — What Actually Changed
The Inflation Reduction Act of 2022 represented the most significant change to US drug pricing policy in decades. For the first time it allowed Medicare to negotiate prices directly with manufacturers for a defined set of high-cost drugs. The first ten drugs subject to negotiation were announced in 2023, with negotiated prices taking effect in 2026. The law also capped Medicare Part D out-of-pocket costs at $2,000 annually starting in 2025 and required manufacturers to pay rebates if they raise prices faster than inflation.
KEY DATA POINT
The negotiated prices announced by CMS in 2024 for the first ten drugs averaged 79% below the drugs’ list prices — including a reduction for Januvia from $527 per month to $113, and for Eliquis from $521 to $231. However the negotiation programme is limited to Medicare and covers only a small fraction of total drug spending in the first years of implementation.
Insulin — A Case Study in Drug Pricing
Insulin has become a symbol of US drug pricing dysfunction. The base compound was discovered in 1921 and its patents were sold to the University of Toronto for $1. Yet the price of insulin in the United States rose more than 1,000% between 1996 and 2019, driven by reformulations that extended manufacturer exclusivity and by the dynamics of the PBM rebate system. Patients rationing insulin — a life-sustaining medication — became a visible and politically galvanising issue.
In response several manufacturers announced voluntary price reductions and the Inflation Reduction Act capped insulin copays at $35 per month for Medicare beneficiaries. Congress failed to pass a $35 cap for private insurance. Some states have enacted their own caps. The situation illustrated both how dysfunctional the pricing system had become and how difficult systemic reform has proven to be.
THE BOTTOM LINE
US prescription drug prices reflect a system of interlocking incentives — manufacturer pricing power, patent strategies, PBM rebate dynamics, and the absence of government price negotiation — that has historically produced high prices with no single party bearing full accountability for the outcome.
Explore Individual Drug Pricing Questions
Get clear answers on prescription drug pricing — from how PBMs work to what the Inflation Reduction Act actually changed to why GoodRx sometimes beats your insurance.
2 Comments
Comments are closed.